Original Article

Vaccine potential of LenA and LcpA proteins of Leptospira interrogans in combination with Escherichia coli heat-labile enterotoxin, B subunit (LTB)


Background and Objectives: Leptospirosis is a zooanthroponosis caused by the genus of Leptospira. It is an emerging public health problem due to its increasing incidence. The achievement to a vaccine that prevent from entrance of Leptospira interrogans to the deeper tissues of the host is needed. This study aimed to investigate the immunogenicity of LcpA (rLcpA) and LenA (rLenA) recombinant proteins in combination with LTB (rLTB) recombinant protein as an adjuvant against leptospiral infection in hamsters.
Materials and Methods: The genes encoding these proteins were cloned into pGH cloning vector and then lenA, lcpA and ltb genes subcloned into pET-15b and pET-28a expression vectors, respectively. The hamsters were immunized with the purified recombinant proteins and challenged with Leptospira interrogans for evaluation of their survival. The antibody responses to the recombinant proteins were determined by ELISA. Then, data entered into SPSS software. Statistical Kruskal–Wallis test was used to compare the significant differences among different groups. The groups with significant differences were further analyzed by post hoc tests. The p value < 0.05 statistically was considered significant.
Results: Immunized hamsters with rLenA-plus-rLTB, rLcpA-plus-rLTB and rLenA-plus-rLcpA-plus-rLTB proteins showed 60%, 74%, and 80% survival rates, respectively. A significant amount of interleukin-17 (IL-17), interleukin-4 (IL-4) and gamma interferon (IFNγ) cytokines were produced in immunized hamsters.
Conclusion: Based on our findings, rLcpA and rLenA proteins in combination with rLTB can protect the hamsters against L. interrogans and effectively induce a protective antibody response. Thus, these proteins can be used as an additional prophylactic tool against leptospira.

1. Faraji H, Mirzaei H, Afshar D, Nouri P, Roshanjo K, Mohamadi Bardebari A, et al. The epidemiology of Leptospira infection in Mazandaran province, northern Iran, during 2012 - 2013. Iran Red Crescent Med J 2016;18(7): e23194.
2. Vijayachari P, Sugunan AP, Shriram AN. Leptospirosis: an emerging global public health problem. J Biosci 2008;33:557-569.
3. Domingos RF, Vieira ML, Romero EC, Gonçales AP, de Morais ZM, Vasconcellos SA, et al. Features of two proteins of Leptospira interrogans with potential role in host-pathogen interactions. BMC Microbiol 2012; 12:50.
4. Barbosa AS, Monaris D, Silva LB, Morais ZM, Vasconcellos SA, Cianciarullo AM, et al. Functional characterization of LcpA, a surface-exposed protein of Leptospira spp. that binds the human complement regulator C4BP. Infect Immun 2010; 78:3207-3216.
5. Domingos RF, Fernandes LG, Romero EC, de Morais ZM, Vasconcellos SA, Nascimento AL. Novel Leptospira interrogans protein Lsa32 is expressed during infection and binds laminin and plasminogen. Microbiology 2015; 161:851-864.
6. Raja V, Natarajaseenivasan K. Pathogenic, diagnostic and vaccine potential of leptospiral outer membrane proteins (OMPs). Crit Rev Microbiol 2015; 41:1-17.
7. Gamberini M, Gómez RM, Atzingen MV, Martins EA, Vasconcellos SA, Romero EC, et al. Whole-genome analysis of Leptospira interrogans to identify potential vaccine candidates against leptospirosis. FEMS Microbiol Lett 2005; 244:305-313.
8. Palaniappan RU, Chang YF, Jusuf SS, Artiushin S, Timoney JF, McDonough SP, et al. Cloning and molecular characterization of an immunogenic LigA protein of Leptospira interrogans. Infect Immun 2002; 70:5924-5930.
9. Breda LC, Hsieh CL, Castiblanco Valencia MM, da Silva LB, Barbosa AS, Blom AM, et al. Fine Mapping of the Interaction between C4b-Binding Protein and Outer Membrane Proteins LigA and LigB of Pathogenic Leptospira interrogans. PLoS Negl Trop Dis 2015; 9(10):e0004192.
10. Zarantonelli L, Suanes A, Meny P, Buroni F, Nieves C, Salaberry X, et al. Isolation of pathogenic Leptospira strains from naturally infected cattle in Uruguay reveals high serovar diversity, and uncovers a relevant risk for human leptospirosis. PLoS Negl Trop Dis 2018; 12(9):e0006694.
11. Robbins GT, Hahn BL, Evangelista KV, Padmore L, Aranda PS, Coburn J. Evaluation of cell binding activities of Leptospira ECM adhesins. PLoS Negl Trop Dis 2015; 9(4):e0003712.
12. Faine S, Adler B, Bolin C, Perolat P. (1999) Leptospira and Leptospirosis, 2nd edn. MediSci, Melbourne, Australia.
13. Choy HA. Multiple activities of LigB potentiate virulence of Leptospira interrogans: inhibition of alternative and classical pathways of complement. PLoS One 2012; 7(7):e41566.
14. Barbosa AS, Monaris D, Silva LB, Morais ZM, Vasconcellos SA, Cianciarullo AM, et al. Functional characterization of LcpA, a surface-exposed protein of Leptospira spp. that binds the human complement regulator C4BP. Infect Immun 2010; 78:3207-3216.
15. da Silva LB, Miragaia Ldos S, Breda LC, Abe CM, Schmidt MC, Moro AM, et al. Pathogenic Leptospira species acquire factor H and vitronectin via the surface protein LcpA. Infect Immun 2015; 83:888-897.
16. Silva EF, Medeiros MA, McBride AJ, Matsunaga J, Esteves GS, Ramos JG, et al. The terminal portion of leptospiral immunoglobulin-like protein LigA confers protective immunity against lethal infection in the hamster model of leptospirosis. Vaccine 2007; 25:6277-6286.
17. Gonçalves-de-Albuquerque CF, Burth P, Silva AR, Younes-Ibrahim M, Castro-Faria-Neto HC, Castro-Faria MV. Leptospira and inflammation. Mediators Inflamm 2012; 2012:317950.
18. Dellagostin OA, Grassmann AA, Rizzi C, Schuch RA, Jorge S, Oliveira TL, et al. Reverse vaccinology: an approach for identifying Leptospiral vaccine candidates. Int J Mol Sci 2017; 18:158.
19. Teixeira AF, Fernandes LGV, Souza Filho A, Souza GO, Vasconcellos SA, Heinemann MB, et al. Evaluation of Lsa46 and Lsa77 Leptospiral proteins for their immunoprotective activities in hamster model of Leptospirosis. Biomed Res Int 2018; 2018:1813745.
20. Grassmann AA, Kremer FS, Dos Santos JC, Souza JD, Pinto LDS, McBride AJA. Discovery of novel Leptospirosis vaccine candidates using reverse and structural vaccinology. Front Immunol 2017; 8:463.
21. Oliveira TL, Grassmann AA, Schuch RA, Seixas Neto AC, Mendonça M, Hartwig DD, et al. Evaluation of the Leptospira interrogans Outer membrane protein OmpL37 as a vaccine candidate. PLoS One 2015; 10(11):e0142821.
22. Conrad NL, Cruz McBride FW, Souza JD, Silveira MM, Félix S, Mendonça KS, et al. LigB subunit vaccine confers sterile immunity against challenge in the hamster model of leptospirosis. PLoS Negl Trop Dis 2017; 11(3):e0005441.
23. Grassmann AA, Félix SR, dos Santos CX, Amaral MG, Seixas Neto AC, Fagundes MQ, et al. Protection against lethal leptospirosis after vaccination with LipL32 coupled or coadministered with the B subunit of Escherichia coli heat-labile enterotoxin. Clin Vaccine Immunol 2012; 19:740-745.
24. Lin X, Xiao G, Luo D, Kong L, Chen X, Sun D, et al. Chimeric epitope vaccine against Leptospira interrogans infection and induced specific immunity in guinea pigs. BMC Microbiol 2016; 16:241.
25. Zuerner RL, Alt DP, Palmer MV, Thacker TC, Olsen SC. A Leptospira borgpetersenii serovar Hardjo vaccine induces a Th1 response, activates NK cells, and reduces renal colonization. Clin Vaccine Immunol 2011; 18:684-691.
IssueVol 11 No 1 (2019) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijm.v11i1.703
Immunogenicity Leptospira interrogans Recombinant proteins Vaccine

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Ghazali-Bina M, Pourmand MR, Mirshafiey A, Bakhtiari R, Khaledi A, Kazemian H, Afshar D, Getso MI, Eshraghi S. Vaccine potential of LenA and LcpA proteins of Leptospira interrogans in combination with Escherichia coli heat-labile enterotoxin, B subunit (LTB). Iran J Microbiol. 2019;11(1):39-47.